Literature DB >> 15262762

Mucoepidermoid carcinoma of the parotid gland: the Mayo clinic experience.

Derek Kofi O Boahene1, Kerry D Olsen, Jean E Lewis, A Daniel Pinheiro, Vernon Shane Pankratz, Stephanie M Bagniewski.   

Abstract

OBJECTIVE: To determine clinical and histopathologic features of mucoepidermoid carcinoma of the parotid gland, specifically, the relation of tumor stage and grade and treatment type with clinical outcome.
DESIGN: Retrospective clinical and histopathologic review.
SETTING: Tertiary care medical center. PATIENTS: From 1940 to 1994, 128 patients were treated at our institution for parotid mucoepidermoid carcinoma. Eighty-nine of these patients had their first treatment at our institution; these cases were chosen for retrospective clinical and histopathologic review. INTERVENTION: A head and neck pathologist independently reviewed the pathology specimens. MAIN OUTCOME MEASURES: Age, symptoms, stage, treatment type, tumor grade, pathological features, disease progression, and survival.
RESULTS: Results of clinical staging were: T1 in 56 patients, T2 in 13, T3 in 1, T4 in 15, N0 in 85, N1 in 2, and N2 in 2. No patient had N3 or M1 disease. All patients underwent parotidectomy with or without neck dissection. Seven patients received postoperative radiotherapy. Tumor grade was low in 43 patients (48%), intermediate in 40 (45%), and high in 6 (7%). Only 5 patients had disease progression (local recurrence in 4, regional recurrence in 4, and distant recurrence in 2). At latest follow-up (mean follow-up, 14.7 years), 64 patients were alive without disease, 1 was alive with disease, 2 had died of mucoepidermoid carcinoma, and 22 had died of other causes. The Kaplan-Meier estimated cancer-specific survival rates at 5, 15, and 25 years were 98.8%, 97.4%, and 97.4%, respectively.
CONCLUSIONS: In our study, tumor grade and stage appeared to be less important than previously described. With adequate parotidectomy and appropriate neck dissection, patients with mucoepidermoid carcinoma of the parotid gland appear to do well, with few recurrences.

Entities:  

Mesh:

Year:  2004        PMID: 15262762     DOI: 10.1001/archotol.130.7.849

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  19 in total

1.  Expression of mucin (MUC) genes in mucoepidermoid carcinoma.

Authors:  Nima Shemirani; Vladimir Osipov; Alex Kolker; Pawjai Khampang; Joseph E Kerschner
Journal:  Laryngoscope       Date:  2011-01       Impact factor: 3.325

Review 2.  [Salivary gland carcinomas Part II. Diagnosis and therapy].

Authors:  S Lang; N Rotter; A Lorenzen; S Ihrler; R Eckel; D Hölzel; G Rasp; B Wollenberg; K Sommer
Journal:  HNO       Date:  2005-10       Impact factor: 1.284

3.  Deep lobe parotidectomy: clinical rationale in the management of primary and metastatic cancer.

Authors:  Kerry D Olsen; Eric J Moore
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-07-06       Impact factor: 2.503

4.  Parotid carcinoma: Current diagnostic workup and treatment.

Authors:  Vincent L M Vander Poorten; Francis Marchal; Sandra Nuyts; Paul M J Clement
Journal:  Indian J Surg Oncol       Date:  2010-11-21

5.  Mucoepidermoid Carcinoma of the Salivary Glands: Survival and Prognostic Factors.

Authors:  Guevara-Canales Janet-Ofelia; Morales-Vadillo Rafael; Guzmán-Arias Guillermo; Cava-Vergiú Carlos-Enrique; Robello-Malatto José-Martín; Guerra-Miller Henry; Montes-Gil Jaime-Enrique
Journal:  J Maxillofac Oral Surg       Date:  2016-07-29

Review 6.  Contemporary management of tumors of the salivary glands.

Authors:  Joseph M Scianna; Guy J Petruzzelli
Journal:  Curr Oncol Rep       Date:  2007-03       Impact factor: 5.075

7.  Primary and non-primary parotid malignancies: comparison of treatment modalities and outcomes.

Authors:  Sylvain Morinière; Sophie Périé; Jean Lacau St Guily
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-05-30       Impact factor: 2.503

8.  Treatment and survival outcomes based on histologic grading in patients with head and neck mucoepidermoid carcinoma.

Authors:  Melonie A Nance; Raja R Seethala; Yun Wang; Simion I Chiosea; Eugene N Myers; Jonas T Johnson; Stephen Y Lai
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

9.  Deep lobe parotidectomy-why, when, and how?

Authors:  Kerry D Olsen; Miquel Quer; Remco de Bree; Vincent Vander Poorten; Alessandra Rinaldo; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-10-12       Impact factor: 2.503

10.  Colonic metastasis in mucoepidermoid carcinoma of the parotid: a rare occurrence.

Authors:  Jenifer Jeba; Mayur Suryawanshi; Pranay Gaikwad; Selvamani Backianathan
Journal:  BMJ Case Rep       Date:  2016-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.